Jan 22 (Reuters) - Moderna does not plan to invest in new late-stage vaccine trials because of growing opposition to ...
CEO Stéphane Bancel said on Thursday that his company will not fund further late-stage development of vaccines as the U.S.
The firm is expecting a slew of key readouts for mRNA vaccines for treating cancer and rare diseases and is exploring vaccines for autoimmune conditions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback